20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
08:00 , Dec 21, 2015 |  BioCentury  |  Politics, Policy & Law

Trans-Pacific dreams

If Republicans in Congress move past their disappointment with biologics exclusivity provisions and ratify the Trans-Pacific Partnership trade treaty, the stage will be set for a significant strengthening of global IP protections for pharmaceuticals. The...
07:00 , Oct 24, 2011 |  BioCentury  |  Regulation

Cracking open FDA

A window has opened in Washington for reformers from both parties to revamp FDA 's oversight of medical products, but the opening is narrow and will slam shut quickly. Reform proposals will be adopted only...
08:00 , Nov 13, 2006 |  BioCentury  |  Politics, Policy & Law

Populist peril

Some things change, some remain the same. Following last week's mid-term elections in the U.S., the biggest challenge to new drug development in Washington remains the same as it was under Republican leadership: regulatory reform....
07:00 , Apr 17, 2006 |  BioCentury  |  Regulation

Zero hour nears in Europe

FDA's 'Egregious' Delays Zero hour nears in Europe Compared to the U.S., where follow-on biologics are creeping toward the market, Europe is racing forward. European consumers could be seeing FOBs - biosimilars in Eurospeak -...
08:00 , Jan 3, 2005 |  BC Week In Review  |  Company News

Ardent, Enhance Biotech deal

EBOI completed its previously announced merger with Ardent (see BioCentury, Aug. 16, 2004). EBOI shareholders own 55% of the combined company, and Ardent shareholders own the remaining 45%. EBOI CEO Chris Every becomes president, CEO...
08:00 , Nov 8, 2004 |  BC Week In Review  |  Company News

Ardent, J&J deal

Ardent granted JNJ subsidiary Alza Corp. (Mountain View, Calif.) a 12-month option to an exclusive worldwide license to DPI-125, a delta/ mu opioid receptor agonist that has completed Phase I testing to treat moderate to...
08:00 , Nov 3, 2004 |  BC Extra  |  Company News

Alza, Ardent in pain deal

Ardent granted Johnson & Johnson (JNJ) subsidiary Alza a 12-month option to an exclusive worldwide license to DPI-125, a delta/ mu opioid receptor agonist that has completed Phase I testing to treat moderate to severe...
07:00 , Aug 16, 2004 |  BC Week In Review  |  Company News

Ardent, Enhance Biotech deal

EBOI will merge with Ardent. Post-merger, EBOI shareholders will own 55% of the combined company, and Ardent shareholders will own the remaining 45%. Ardent is developing therapeutics that target the delta opioid receptor to treat...
07:00 , Jun 21, 2004 |  BioCentury  |  Politics, Policy & Law

Breaking ranks

Divisions in the industry over how to deal with the issue of follow-on biologics are threatening to become highly public, as the Biotechnology Industry Org-anization's efforts to craft a compromise position hasn't bridged the differences...